NewAmsterdam Pharma N.V. (NAMS)
NASDAQ: NAMS
· Real-Time Price · USD
17.41
0.10 (0.58%)
At close: May 29, 2025, 12:44 PM
0.58% (1D)
| Bid | 17.39 |
| Market Cap | 1.95B |
| Revenue (ttm) | 46.99M |
| Net Income (ttm) | -145.24M |
| EPS (ttm) | -1.84 |
| PE Ratio (ttm) | -9.46 |
| Forward PE | -9.13 |
| Analyst | Buy |
| Ask | 17.45 |
| Volume | 131,908 |
| Avg. Volume (20D) | 982,413 |
| Open | 17.47 |
| Previous Close | 17.31 |
| Day's Range | 17.06 - 17.57 |
| 52-Week Range | 14.06 - 27.29 |
| Beta | 0.01 |
About NAMS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NAMS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NAMS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+6.09%
NewAmsterdam Pharma shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
+10.23%
NewAmsterdam Pharma shares are trading higher after the company reported better-than-expected FY24 sales results.
2 months ago · seekingalpha.com
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibNew Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to fi...
2 months ago · seekingalpha.com
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol RevolutionNewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures...